GM.CD40L, a human bystander cell line created at the Moffitt Cancer Center that expresses both granulocyte-macrophage colony-stimulating factor (GM-CSF) and CD40 ligand (CD40L), has been used to generate an allogeneic tumor cell-based vaccine formulation. This evidence concerns the gene CSF2 and neoplasm.